Sodium valproate (VPA) is considered the first choice drug in juvenile myoclonic epilepsy (JME). We have analysed the longterm evolution of 22 patients treated from the outset with VPA.
INTRODUCTION
Juvenile myoclonic epilepsy (JME) is a common form of idiopathic generalized epilepsy that typically occurs in adolescence. Its clinical features and electroencephalographic findings are well known [1] [2] [3] [4] [5] [6] [7] . Sodium valproate (VPA) is considered the first choice drug in JME 8 . However, there are few published long-term follow-up reports of patients treated from the onset with VPA 9 .
PATIENTS AND METHODS
One hundred and twenty patients with JME are controlled in our Neurological Department. For the present study we applied the following inclusion criteria: (1) unequivocal diagnosis of JME (evidence of myoclonic seizures beginning from the age of 8 upto 20 years of age; no evidence of neurological or intellectual deficit; abnormal EEG with generalized spike-wave and/or multiple spike-wave discharges); (2) treatment should be initiated with VPA monotherapy; and (3) follow-up for more than 5 years.
RESULTS
Twenty-two patients (15 female, seven male) with a mean age of 28 years (range: 20-40 years) and a mean follow-up 7.7 years (range: 5-17 years) were studied. All the patients had myoclonic seizures, 15 (68%) had myoclonic seizures and generalized tonic-clonic seizures (GTCS), four (18%) had myoclonic seizures, GTCS and absence seizures, and three patients (13.6%) had only myoclonic seizures. An average of two (range: 0-8) GTCS was reported.
An average of 0.7 GTCS (range: 0-4) was reported after the onset of VPA treatment.
Myoclonic seizures began on average at 16.5 years (range: 12-22 years); GTCS began on average at 17.8 years (range: 14-30 years). The average age at which JME was definitively diagnosed was 18.9 years (range: 13-27 years), after a mean of 2.4 years (range: 0-12 years) from the onset of the myoclonic seizures.
Treatment with VPA was initiated at an average age of 17.4 years (range: 13-24 years). Four patients continued suffering GTCS and a second antiepileptic drug was added to VPA: three of them were controlled on a combination of VPA and lamotrigine; another one was eventually controlled on a combination of VPA and clobazam. Two patients chose voluntarily to discontinue the treatment, and they suffer occasional myoclonic jerks. Another discontinued the treatment on medical orders and she remains seizure-free after 5 years of follow-up (progressive dose reduction was not followed by relapses). Only one (4.4%) patient was receiving anxiolytic treatment with benzodiazepines Twenty patients (90.9%) became seizure-free: six of them (27.3%) have remained seizure-free for more than 5 years. Of these patients, five were receiving VPA monotherapy. The other one was not receiving any treatment at all. Only two patients (9.1%) occasionally relapse. All patients who did not discontinue medication are seizure-free. Of them, 16 relapsed, after attempts to reduce the dose of VPA: three patients developed GTCS and 13 had only myoclonic seizures (Fig. 1) .
The average daily dose of VPA was 850 mg per day (range: 500-1500 mg per day) and the average blood levels were 513 µmol l −1 (range: 35-908 µmol l −1 ). The average dose of lamotrigine was 165 mg (range: 100-200 mg per day).
We reviewed 148 EEG recordings. Each patient had a mean of 6.7 EEG recordings. At the time of the first record 40.9% of the patients were receiving VPA. Only 56% of their standard EEG recordings had pathological findings, whereas 89% of their sleep EEGs showed paroxysmal abnormalities. Among the patients who were not receiving antiepileptic drugs at the time of the first recordings, 69% of the standard EEGs had pathological findings, whereas 100% of their sleep EEGs showed paroxysmal abnormalities. Normal standard EEGs were reported in every patient during the follow-up, although they did occasionally show paroxysmal abnormalities, but 89% of the sleep EEGs at the follow-up continued show pathological findings.
Nine patients (40.9%) displayed a photoparoxysmal response. This occurred in six (67%) females and three (33%) males. The patients that have remained seizurefree for more than 5 years have a lower rate of photoparoxysmal response (16%).
Focal abnormalities were noted in at least one EEG in six (27.3%) of the 22 patients (five females (83.3%) and one male (16.7%)).
DISCUSSION
Despite the distinctive features of JME and the significance of diagnosis for management and prognosis, JME is widely underdiagnosed 5 . In our patients the correct diagnosis was made after a mean of 2.4 years (range: 0-12 years) from the onset of the disease. This is in reality a lower interval than the 14.5 years referred to by Grünewald et al. 10 or the 10.6 years detected by Salas-Puig et al. 6 The latter studied a population similar to ours 10 years earlier. Thus, the diagnosis yield can be improved with heightened medical awareness. JME is characterized by myoclonic jerks, occurring mainly on awakening and often associated with GTCS and typical absence seizures in an age-related sequence. The clinical characteristics of our patients compare well with those of previous reports. An important feature in our patients was that only an average of 0.7 GTCS (range: 0-4) were reported after the onset of VPA treatment.
According to the original description by Janz and Christian 1 , patients often have an unstable personality, which may lead to social maladjustment. However no particular psychiatric condition can be considered as significantly associated. Salas-Puig et al. 6 reported that 13% of their patients were being treated with benzodiazepines, antidepressants or even neuroleptics. In our study only one patient (4.5%) is receiving anxyolitic treatment. This figure suggests that an early and appropiate therapy probably would prevent the appearance of psychopathological disorders.
Interictal and ictal EEG findings are very characteristic 11 . The EEG in untreated patients usually shows generalized spike or multiple spike/wave discharges. Focal abnormalities are common 12 . These consist on either focal onset of the generalized discharge or focal slow waves that may be unilateral or may shift sides. Spontaneous jerks are always associated with generalized multiple spike-wave discharges.
Photoparoxysmal responses (PPR) have been found in 33% of the patients for Asconapé and Penry 2 , 32% for Salas-Puig et al. 6 , 27% for Panayiotopoulos et al. 7 and 33% for Grünewald et al. 10 . We found PPR in 30% of our patients at the time of the first EEG recording, but in only 5% at the follow-up.
Photosensitivity is more common in females than in males (67% of our photosensitive patients were females). Among the patients of our study with a better evolution (those who have been seizure-free for more than 5 years) only 16% had EEG evidence of photosensitivity. Apparently focal paroxysmal abnormalities were noted in 27.3% of our patients. These focal EEG abnormalities were found in 15% of the patients by Salas-Puig et al. 6 and in 30% by Asconapé and Penry 2 .
Among the patients of our study who were not being treated at the time of the first EEG recording, a typical pattern of paroxysmal abnormalities was found in 69% of the standard EEG recordings, but in 100% of the sleep recordings during a nap period. At the follow-up 100% of the patients had normal standard EEG records (though eventually paroxysmal abnormalities could be found). However, 89% of the sleep EEGs at the followup continued to show pathological findings. A sleep EEG recording should be requested when the routine EEG is normal and further confirmation of the diagnosis is required.
Patients should be warned of the common seizure precipitants. The most effective antiepileptic drug for this condition is VPA, and most authors recommend lifelong therapy 8 . If seizures persist despite this treatment patients may benefit from the addition of lamotrigine.
All of our patients were treated from the outset with VPA monotherapy. Eighteen point two percent of them, with persistent GTCS despite optimal VPA dosage, were treated by adding small doses of a second drug: lamotrigine in three cases (they were completely controlled and they continued this treatment during follow-up) and clobazam in one case (this patient was completely controlled and clobazam was discontinued).
Three patients have discontinued all treatment: two of them withdrew VPA voluntarily and they are the only patients of our study who continue suffering myoclonic seizures; in another one VPA was able to be discontinued without relapses. This patient seems to have a very benign form of JME. When we analysed her case, however, we were not able to find any characteristic that would have made us suspect a good outcome. Her awake EEG is normal but her sleep EEG recording continues to show paroxysmal abnormalities.
All of our patients who continue their treatment are seizure-free. The reported effective control of seizures ranges from 54% (Asconapé and Penry 2 ) to 95% (Christe 9 ). Antiepileptic drugs and periods of followup are heterogeneous. The drug of choice, however, is currently VPA on monotherapy which effectively controlled all seizures in 73% of our patients in spite of low doses and low blood levels.
The discontinuation of drug therapy leads to a very high rate of relapse. In our study 73% of the patients have suffered relapses. These occurred weeks or months after the discontinuation of treatment in all of our patients except for one. Relapses occurred as GTCS in three of the relapsing patients (18.7%); 13 of them (81.2%) had only myoclonic relapses. These rates compare well with those reported by Janz 4 (91%) and Penry 8 (50%) and suggest that treatment should not be discontinued even after patients have been seizure-free for a long time.
